{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T21:47:34Z","timestamp":1775166454639,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009022","name":"Newcrest Mining","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003550","name":"Queensland Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010230","name":"Queensland Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health and Aged Care, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008914","name":"Queensland Government Advance Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014711","name":"Institute for Molecular Bioscience, University Of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021113","name":"Bowness Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021113","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ebiom.2023.104842","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T04:57:38Z","timestamp":1697777858000},"page":"104842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18\u201355 years or \u226556 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8636-5067","authenticated-orcid":false,"given":"Keith J.","family":"Chappell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca L.","family":"Mordant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto A.","family":"Amarilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naphak","family":"Modhiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3304-4715","authenticated-orcid":false,"given":"Benjamin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danushka K.","family":"Wijesundara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-3998","authenticated-orcid":false,"given":"Julia A.","family":"Lackenby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian K.","family":"Bennet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Hensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi H.O.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Tapley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick C.","family":"Reading","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Kedzierska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charani","family":"Ranasinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Watterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trent P.","family":"Munro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2023.104842_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.961198","article-title":"Fast-track development of vaccines for SARS-CoV-2: the shots that saved the world","volume":"13","author":"Chavda","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2023.104842_bib2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3390\/vaccines10101655","article-title":"A\u00a0comprehensive review on the current vaccines and their efficacies to combat SARS-CoV-2 variants","volume":"10","author":"Rabaan","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ebiom.2023.104842_bib3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMc2108829","article-title":"Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination","volume":"385","author":"Barouch","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104842_bib4","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMc2115596","article-title":"Differential kinetics of immune responses elicited by Covid-19 vaccines","volume":"385","author":"Collier","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104842_bib5","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2023.104842_bib6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104842_bib7","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3390\/vaccines10101757","article-title":"Post-vaccination neutralization responses to Omicron sub-variants","volume":"10","author":"Jacobsen","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ebiom.2023.104842_bib8","article-title":"Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant","volume":"3","author":"Lyke","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ebiom.2023.104842_bib9","doi-asserted-by":"crossref","first-page":"e1269","DOI":"10.1002\/cti2.1269","article-title":"Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2","volume":"10","author":"Watterson","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.ebiom.2023.104842_bib10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(21)00200-0","article-title":"Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"21","author":"Chappell","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2023.104842_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.625136","article-title":"An optimized high-throughput immuno-plaque assay for SARS-CoV-2","volume":"12","author":"Amarilla","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ebiom.2023.104842_bib12","article-title":"Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2023.104842_bib13","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/cid\/ciab381","article-title":"Age-dependent immune response to the Biontech\/Pfizer BNT162b2 coronavirus disease 2019 vaccination","volume":"73","author":"M\u00fcller","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2023.104842_bib14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2023.104842_bib15","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104842_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.758294","article-title":"The impact of age difference on the efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2023.104842_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.918896","article-title":"Immunogenicity, effectiveness, and safety of inactivated virus (CoronaVac) vaccine in a two-dose primary protocol and BNT162b2 heterologous booster in Brazil (Immunita-001): a one year period follow up Phase 4 study","volume":"13","author":"Grenfell","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2023.104842_bib18","first-page":"795","article-title":"Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial","volume":"84","author":"Liu","year":"2022","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.ebiom.2023.104842_bib19","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104842_bib20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"Munro","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2023.104842_bib21","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/cid\/ciac345","article-title":"Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 Omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial","volume":"75","author":"Poh","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2023.104842_bib22","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1080\/22221751.2022.2088406","article-title":"Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ebiom.2023.104842_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2017.06.005","article-title":"Old and new adjuvants","volume":"47","author":"McKee","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ebiom.2023.104842_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.571416","article-title":"Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections?","volume":"11","author":"Bajaj","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.ebiom.2023.104842_bib25","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ni.2588","article-title":"Understanding immunosenescence to improve responses to vaccines","volume":"14","author":"Goronzy","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ebiom.2023.104842_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ebiom.2023.104842_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-022-00978-0","article-title":"SARS-CoV-2-specific CD4+ T cells are associated with long-term persistence of neutralizing antibodies","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ebiom.2023.104842_bib28","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104842_bib29","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104842_bib30","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423004085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423004085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:28:22Z","timestamp":1762457302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396423004085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":30,"alternative-id":["S2352396423004085"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104842","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18\u201355 years or \u226556 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104842"}}